Suppr超能文献

体液和转移因子在恶性肿瘤高钙血症发病机制中的相对作用。

Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy.

作者信息

Ralston S H, Fogelman I, Gardiner M D, Boyle I T

出版信息

Br Med J (Clin Res Ed). 1984 May 12;288(6428):1405-8. doi: 10.1136/bmj.288.6428.1405.

Abstract

Some relations between metastatic bone disease and calcium homoeostasis were determined in a consecutive series of 81 patients with solid malignant tumours attending for radionuclide bone scans. Biochemical evaluation showed that bone resorption from metastatic disease was generally not enough to account for hypercalcaemia. While skeletal metastases were present in about half of the patients who developed hypercalcaemia, biochemical indices of bone resorption in these subjects were greatly increased and disproportionate to the extent of metastatic disease detected by the bone scans. Furthermore, a reduced renal phosphate threshold and increased tubular calcium reabsorption were generally observed in hypercalcaemic patients when compared with their normocalcaemic counterparts. These findings suggest that in most cases malignancy associated hypercalcaemia may be caused by the release of a humoral factor by tumour tissue which exhibits "parathyroid-hormone-like" activity with regard to bone resorption, renal phosphate threshold, and renal calcium handling. It may be postulated that this putative humoral mediator predisposes to hypercalcaemia both by stimulating generalised osteolysis and in most cases also by impairing the renal excretion of the resultant increase in filtered calcium load. While hypercalcaemia may arise as a result of metastatic bone disease alone, these data indicate that this may be the exception rather than the rule. Hence the term "metastatic hypercalcaemia" should probably be reserved for patients with extensive skeletal tumour disease in whom biochemical evaluation fails to yield evidence of an underlying humorally mediated cause.

摘要

在对81例因进行放射性核素骨扫描而就诊的实体恶性肿瘤患者进行的连续研究中,确定了转移性骨病与钙稳态之间的一些关系。生化评估显示,转移性疾病引起的骨吸收通常不足以解释高钙血症。虽然约一半发生高钙血症的患者存在骨转移,但这些患者的骨吸收生化指标大幅升高,与骨扫描检测到的转移疾病程度不相称。此外,与血钙正常的患者相比,高钙血症患者通常观察到肾磷酸盐阈值降低和肾小管钙重吸收增加。这些发现表明,在大多数情况下,恶性肿瘤相关的高钙血症可能是由肿瘤组织释放一种体液因子引起的,该因子在骨吸收、肾磷酸盐阈值和肾钙处理方面表现出“甲状旁腺激素样”活性。可以推测,这种假定的体液介质通过刺激全身性骨溶解,并且在大多数情况下还通过损害肾脏对滤过钙负荷增加的排泄,从而导致高钙血症。虽然高钙血症可能仅由转移性骨病引起,但这些数据表明这可能是例外而非普遍规律。因此,“转移性高钙血症”一词可能应仅用于那些骨骼肿瘤广泛且生化评估未能提供潜在体液介导原因证据的患者。

相似文献

1
Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy.
Br Med J (Clin Res Ed). 1984 May 12;288(6428):1405-8. doi: 10.1136/bmj.288.6428.1405.
2
Mechanism of malignant hypercalcaemia in carcinoma of the breast.
Br Med J (Clin Res Ed). 1985 Sep 21;291(6498):776-9. doi: 10.1136/bmj.291.6498.776.
3
Hypercalcaemia and metastatic bone disease: is there a causal link?
Lancet. 1982 Oct 23;2(8304):903-5. doi: 10.1016/s0140-6736(82)90868-6.
6
Parathyroid hormone related protein and hypercalcaemia in breast cancer.
BMJ. 1991 Dec 14;303(6816):1506-9. doi: 10.1136/bmj.303.6816.1506.
10
Hypercalcaemia of malignancy.
Cancer Metastasis Rev. 1989 Jun;8(1):23-52. doi: 10.1007/BF00047056.

引用本文的文献

1
Treatment of malignancy-associated hypercalcemia with cinacalcet: a paradigm shift.
Endocr Connect. 2021 Jan;10(1):R13-R24. doi: 10.1530/EC-20-0487.
2
Hypercalcaemia and hypocalcaemia: finding the balance.
Support Care Cancer. 2017 May;25(5):1639-1649. doi: 10.1007/s00520-016-3543-1. Epub 2017 Jan 12.
3
Non-malignant causes of hypercalcemia in cancer patients: a frequent and neglected occurrence.
Support Care Cancer. 2013 May;21(5):1415-9. doi: 10.1007/s00520-012-1683-5. Epub 2012 Dec 11.
4
Hypercalcemia of malignancy.
Rev Endocr Metab Disord. 2000 Nov;1(4):253-63. doi: 10.1023/a:1026597816193.
5
Hypercalcaemia: historical perspectives and present management.
Support Care Cancer. 1993 Jan;1(1):19-25. doi: 10.1007/BF00326635.
6
The management of hypercalcemia of malignancy.
Support Care Cancer. 1995 Mar;3(2):123-9. doi: 10.1007/BF00365852.
8
Mechanism of malignant hypercalcaemia in carcinoma of the breast.
Br Med J (Clin Res Ed). 1985 Sep 21;291(6498):776-9. doi: 10.1136/bmj.291.6498.776.
9
3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer.
Br J Cancer. 1987 Oct;56(4):465-9. doi: 10.1038/bjc.1987.225.

本文引用的文献

1
Hypercalcemia in neoplastic disease.
Arch Surg. 1960 Feb;80:308-18. doi: 10.1001/archsurg.1960.01290190128024.
2
Rehydration in the treatment of severe hypercalcaemia.
Q J Med. 1981 Autumn;50(200):473-81.
3
Predictive value of derived calcium figures based on the measurement of ionised calcium.
Ann Clin Biochem. 1981 Mar;18 (Pt 2):106-9. doi: 10.1177/000456328101800210.
4
Calcium excretion (CaE) in metastatic breast cancer.
Br J Surg. 1983 Apr;70(4):202-4. doi: 10.1002/bjs.1800700405.
5
The hypercalcemia of malignancy: pathogenesis and management.
Metabolism. 1982 Dec;31(12):1247-77. doi: 10.1016/0026-0495(82)90012-9.
8
Hypercalcaemia and metastatic bone disease: is there a causal link?
Lancet. 1982 Oct 23;2(8304):903-5. doi: 10.1016/s0140-6736(82)90868-6.
9
Pseudohyperparathyroidism.
Medicine (Baltimore). 1966 May;45(3):247-60. doi: 10.1097/00005792-196605000-00004.
10
The relation between serum calcium and tumor metastases.
Surg Gynecol Obstet. 1969 Feb;128(2):369-74.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验